Edition:
United States

People: C R Bard Inc (BCR)

BCR on New York Consolidated

308.70USD
26 May 2017
Change (% chg)

$0.11 (+0.04%)
Prev Close
$308.59
Open
$308.40
Day's High
$308.94
Day's Low
$307.95
Volume
451,830
Avg. Vol
858,853
52-wk High
$309.16
52-wk Low
$203.63

Weiland, John 

Mr. John H. Weiland is President, Vice Chairman of the Board, Chief Operating Officer of the Company. Mr. Weiland was elected as Vice Chairman in August 2016 and has served as President and Chief Operating Officer of the Company since August 2003, having been Group President from April 1997 to August 2003 and Group Vice President from March 1996 to April 1997. Mr. Weiland joined C. R. Bard from Dentsply International, where he was a Senior Vice President, until March 1996. He is also a director of West Pharmaceutical Services, Inc. Mr. Weiland has been nominated to serve an additional term as a director as a result of his extensive knowledge and experience in the medical device industry, his prior service on C. R. Bard’s Board, and more than 20 years of experience in various leadership capacities at the Company. Mr. Weiland joined C. R. Bard in 1996 as Group Vice President and was promoted to Group President in 1997, with responsibility for C. R. Bard’s Surgical, Urological and Endoscopic Technology businesses, and its worldwide manufacturing operations. He was promoted to President and Chief Operating Officer in August 2003. Mr. Weiland also held senior management positions at Dentsply International, American Hospital Supply and Baxter Healthcare. In 1987, he was named a White House Fellow and served as a Special Assistant to two members of President Reagan’s cabinet. Mr. Weiland is a 2012 recipient of the prestigious Horatio Alger Award and serves as a director of the Horatio Alger Association. Mr. Weiland received a B.S. in Biology from DeSales University and an M.B.A. from New York University.

Basic Compensation

Total Annual Compensation, USD 913,610
Restricted Stock Awards, USD 2,378,490
Long-Term Incentive Plans, USD --
All Other, USD 3,828,900
Fiscal Year Total, USD 7,121,000

Options Compensation

  Quantity Market Value
Exercisable 514,860 16,366,600.00
Unexercisable 292,635 11,698,600.00
Exercised 11,190 1,364,960.00
Name Fiscal Year Total

Timothy Ring

12,626,500

John Weiland

7,121,000

James Beasley

4,290,960

Timothy Collins

4,309,940

John Groetelaars

--

Christopher Holland

3,949,350
As Of  30 Dec 2016